DE60016393D1 - Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe - Google Patents

Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe

Info

Publication number
DE60016393D1
DE60016393D1 DE60016393T DE60016393T DE60016393D1 DE 60016393 D1 DE60016393 D1 DE 60016393D1 DE 60016393 T DE60016393 T DE 60016393T DE 60016393 T DE60016393 T DE 60016393T DE 60016393 D1 DE60016393 D1 DE 60016393D1
Authority
DE
Germany
Prior art keywords
glp
blooded
ischemic
tissue
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60016393T
Other languages
English (en)
Other versions
DE60016393T3 (de
DE60016393T2 (de
Inventor
R Coolidge
R Ehlers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60016393(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of DE60016393D1 publication Critical patent/DE60016393D1/de
Application granted granted Critical
Publication of DE60016393T2 publication Critical patent/DE60016393T2/de
Publication of DE60016393T3 publication Critical patent/DE60016393T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE60016393T 1999-04-30 2000-04-27 Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe Expired - Lifetime DE60016393T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US302596 1999-04-30
US09/302,596 US6284725B1 (en) 1998-10-08 1999-04-30 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
PCT/US2000/011251 WO2000066138A2 (en) 1999-04-30 2000-04-27 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
EP00926404A EP1173197B2 (de) 1999-04-30 2000-04-27 Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe

Publications (3)

Publication Number Publication Date
DE60016393D1 true DE60016393D1 (de) 2005-01-05
DE60016393T2 DE60016393T2 (de) 2006-02-02
DE60016393T3 DE60016393T3 (de) 2012-07-12

Family

ID=23168436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016393T Expired - Lifetime DE60016393T3 (de) 1999-04-30 2000-04-27 Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe

Country Status (16)

Country Link
US (3) US6284725B1 (de)
EP (2) EP1512410A1 (de)
JP (1) JP2002543142A (de)
CN (1) CN1349409A (de)
AT (1) ATE283701T1 (de)
AU (2) AU777019B2 (de)
CA (1) CA2372947C (de)
DE (1) DE60016393T3 (de)
ES (1) ES2233366T5 (de)
HK (1) HK1046640A1 (de)
IL (2) IL145830A0 (de)
MX (1) MXPA01010859A (de)
NO (1) NO325601B1 (de)
NZ (1) NZ514610A (de)
PT (1) PT1173197E (de)
WO (1) WO2000066138A2 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP2062593A3 (de) 2000-12-01 2011-08-17 Takeda Pharmaceutical Company Limited Verfahren zur Herstellung einer Zubereitung mit bioaktiven Peptiden
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
EP1525219B1 (de) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 und behandlungsmethode für diabetes
MXPA05003335A (es) * 2002-10-02 2005-07-05 Zealand Pharma As Compuestos de exendina-4 estabilizados.
US7205110B2 (en) * 2002-10-07 2007-04-17 Zymogenetics, Inc. Uses of human Zven antagonists
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1610811A4 (de) * 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc Vorbeugung und behandlung von herzrhythmusstörungen
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004094823A2 (en) 2003-04-23 2004-11-04 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CA2564031A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1888103B1 (de) * 2005-04-11 2012-03-21 Amylin Pharmaceuticals, Inc. Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007033140A2 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
SG173319A1 (en) 2006-03-30 2011-08-29 Valeritas Inc Multi-cartridge fluid delivery device
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CA2724635A1 (en) * 2008-05-19 2009-11-26 Tandem Diabetes Care, Inc. Disposable pump reservoir and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
EP2216042A1 (de) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
EP2724739B1 (de) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Tragbares Infusionspumpensystem
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
MX2013000250A (es) 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
EP2611458B1 (de) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Verwendung von ave0010 für die herstellung eines medikaments zur behandlung von diabetes mellitus typ 2
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950038B2 (en) 2011-08-05 2018-04-24 The Trustees Of The Universiy Of Pennsylvania Methods and compositions for inhibiting delayed graft function
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US11033607B2 (en) 2012-10-26 2021-06-15 University Health Network Peptides and methods for preventing ischemic tissue injury
CA2894765A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HRP20181505T1 (hr) 2013-10-17 2018-11-02 Zealand Pharma A/S Acilirani analozi glukagona
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX381640B (es) 2014-10-29 2025-03-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3296746A1 (de) * 2016-09-20 2018-03-21 Université de Bourgogne In-vitro-verfahren zur diagnose eines frühstadiums von darmischämie
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
DE102020103987A1 (de) * 2020-02-14 2021-08-19 Eberhard Karls Universität Tübingen, Medizinische Fakultät Agens zur Behandlung und Prophylaxe einer postischämischen Gewebeschädigung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61838A (en) * 1867-02-05 Eichaed ketcham
US4196196A (en) 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4976959A (en) 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) † 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
EP0958096A1 (de) 1996-07-11 1999-11-24 Molins Plc Band -schneid-und/oder-schweiss verfahren und gerät
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
EP0996459B1 (de) * 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
US5955594A (en) * 1997-04-30 1999-09-21 Mishra; Lopa Nucleic acids encoding proteins for early liver development
MY155270A (en) † 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
WO2001087322A2 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations

Also Published As

Publication number Publication date
NO20015294D0 (no) 2001-10-29
WO2000066138A2 (en) 2000-11-09
IL145830A0 (en) 2002-07-25
AU4493500A (en) 2000-11-17
US6284725B1 (en) 2001-09-04
NO325601B1 (no) 2008-06-23
ATE283701T1 (de) 2004-12-15
ES2233366T3 (es) 2005-06-16
EP1173197B2 (de) 2011-10-19
PT1173197E (pt) 2005-04-29
CA2372947A1 (en) 2000-11-09
EP1173197B1 (de) 2004-12-01
AU2004240247A1 (en) 2005-01-20
JP2002543142A (ja) 2002-12-17
AU777019B2 (en) 2004-09-30
NO20015294L (no) 2001-12-28
IL145830A (en) 2010-12-30
DE60016393T3 (de) 2012-07-12
HK1046640A1 (zh) 2003-01-24
US6982248B2 (en) 2006-01-03
US20020055460A1 (en) 2002-05-09
MXPA01010859A (es) 2002-05-06
ES2233366T5 (es) 2012-01-27
CA2372947C (en) 2013-02-19
NZ514610A (en) 2004-01-30
CN1349409A (zh) 2002-05-15
EP1512410A1 (de) 2005-03-09
DE60016393T2 (de) 2006-02-02
AU2004240247B2 (en) 2008-07-31
WO2000066138A3 (en) 2001-07-05
EP1173197A2 (de) 2002-01-23
US20020147131A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE283701T1 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE60035987D1 (de) Metabolische intervention mit glp-1 oder seinen biologisch aktiven analogen zur verbesserung der funktion des ischämischen und wiederdurchbluteten gehirns
DE69806246D1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
ATE432289T1 (de) Glp-1 und behandlungsmethode für diabetes
CO5011115A1 (es) Compuestos y metodos quimioquina
DE69836352D1 (de) Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen
PE20040599A1 (es) Amidas sustituidas como moduladores del receptor cannabinoide-1 (cb1)
DE60121145D1 (de) Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln
DK1632483T3 (da) Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander
JP2002532432A5 (de)
DE69328186D1 (de) Zusammensetzung zur behandlung der parkinson-krankheit
CR10167A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de dolor"
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
EP1543158A4 (de) Regulierte aptamer-therapeutika
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
NZ516290A (en) Substituted phenoxyacetic acids
BR0016831A (pt) Composição terapêutica e lente de contato impregnada pela mesma
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
BR0107544A (pt) Composição de promoção de secreção de bile
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
ATE382367T1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 1173197

Country of ref document: EP